- to
Layton Bioscience. In 2002,
Targacept acquired it from Layton,
intending to
repurpose it for CNS conditions.
Targacept voluntarily withdrew mecamylamine...
-
Bradanicline (INN, code name TC-5619) is a drug
which was
being developed by
Targacept that acts as a
partial agonist at the α7
subtype of the
neural nicotinic...
-
development as a
pharmaceutical drug.
Rivanicline Armental M (14 July 2014). "
Targacept Drops Development of Alzheimer's Drug". Wall
Street Journal.
Potter AS...
-
neuronal alpha4beta2
nicotinic receptor,
which is
developed by the
company Targacept. Currently,
there are
several other products developed by
several companies—including...
- TC-2216 is a drug
developed by
Targacept which acts as a
partial agonist at
neural nicotinic acetylcholine receptors and was
researched for the treatment...
- TC-1698 is a drug
developed by
Targacept which acts as a
partial agonist for the α7
subtype of
neural nicotinic acetylcholine receptors. It has neuroprotective...
- is
aimed for
treatment of
multiple diseases and
disorders of the CNS.
Targacept has
three drug
candidates that are in
clinical trials; AZD3480 (TC-1734)...
-
Company (the Summit, NJ site) SU – SUGEN, now
Pfizer TAK –
Takeda TC –
Targacept Inc. TD -
Theravance Biopharma TERN –
Terns Pharma TG –
Tragara Pharmaceuticals...
-
first new building, One
Technology Place,
opened in 2000,
occupied by
Targacept Inc., a
biopharmaceutical company that was spun out of R.J.
Reynolds Tobacco...
